Articles by Mark D. Tyson, MD, MPH

Adapting Urology Practices in the Face of BCG Shortages
BySam S. Chang, MD, MBA,Gary Steinberg, MD, FACS,Mark D. Tyson, MD, MPH,Roger Li, MD,Sandip M. Prasad, MD, MPhil The impact of the BCG shortage on the treatment of bladder cancer, exploring various strategies adopted by urologists to optimize patient care. The conversation highlights the importance of risk stratification in deciding treatment protocols, considering factors like tumor size, location, multifocality, and histology, as well as patient age and overall health.

Appropriate Risk Stratification Intermediate and high-risk Risk Classification
BySam S. Chang, MD, MBA,Gary Steinberg, MD, FACS,Mark D. Tyson, MD, MPH,Roger Li, MD,Sandip M. Prasad, MD, MPhil Experts discuss grading, staging, and risk stratification of Non-Muscle Invasive Bladder Cancer (NMIBC). Panelists highlight differentiation between the risks of recurrence and progression, emphasizing the importance of categorizing patients into low, intermediate, and high-risk groups based on various factors, including tumor size, grade, and history of recurrence. The importance of continuous prospective observation of patients with NMIBC is emphasized.

Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)
BySam S. Chang, MD, MBA,Gary Steinberg, MD, FACS,Mark D. Tyson, MD, MPH,Roger Li, MD,Sandip M. Prasad, MD, MPhil Experts in urology discuss the importance of evaluation to accurately identify the stage and grade of NMIBC, which plays a crucial role in determining the risk category focusing on the distinction between low and high-grade tumors and the significance for each patient with NMIBC.

Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.